Compare NOG & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOG | IDYA |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.6B |
| IPO Year | 2000 | 2019 |
| Metric | NOG | IDYA |
|---|---|---|
| Price | $22.92 | $32.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | $30.56 | ★ $51.08 |
| AVG Volume (30 Days) | ★ 1.9M | 1.0M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,475,723,000.00 | $218,710,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.63 | $306.56 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 11.23 | ★ 3024.43 |
| 52 Week Low | $17.18 | $26.81 |
| 52 Week High | $31.17 | $42.68 |
| Indicator | NOG | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 35.32 | 41.18 |
| Support Level | $19.67 | $29.74 |
| Resistance Level | $27.53 | $35.44 |
| Average True Range (ATR) | 1.04 | 1.50 |
| MACD | -0.69 | -0.10 |
| Stochastic Oscillator | 13.11 | 26.44 |
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.